Edgewise Therapeutics, Inc. (EWTX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 4.26B USD. 52-week range 14.25 to 48.51 USD. Data as of 2026-10-09.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other ...